Rockwell Medical, Inc. (NASDAQ:RMTI) has lost 9.45% during the past week and dropped 29.76% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 10.05%. Rockwell Medical, Inc. (NASDAQ:RMTI) has underperformed the index by 28.58% in the last 4 weeks. Investors should watch out for further signals and trade with caution.

The company shares have rallied 12.7% in the past 52 Weeks. On July 17, 2015 The shares registered one year high of \$18.9 and one year low was seen on December 15, 2014 at \$8.1. The 50-day moving average is \$15.63 and the 200 day moving average is recorded at \$12.13. S&P 500 has rallied 6.56% during the last 52-weeks. The company has received recommendation from many analysts. 2 analysts have rated the company as a strong buy. 1 analysts have suggested buy for the company.1 analyst has also rated it as a strong sell. Rockwell Medical, Inc. is up 26.12% in the last 3-month period. Year-to-Date the stock performance stands at 23.05%. Rockwell Medical, Inc. (NASDAQ:RMTI) : On Friday heightened volatility was witnessed in Rockwell Medical, Inc. (NASDAQ:RMTI) which led to swings in the share price. The shares opened for trading at \$11.53 and hit \$12.79 on the upside , eventually ending the session at \$12.65, with a gain of 9.62% or 1.11 points. The heightened volatility saw the trading volume jump to 1,234,072 shares. The 52-week high of the share price is \$18.8999 and the company has a market cap of \$635 million. The 52-week low of the share price is at \$8.095. Currently the company Insiders own 5.5% of Rockwell Medical, Inc. Company shares. In the past six months, there is a change of 0.73% in the total insider ownership. Institutional Investors own 34.4% of Company shares. During last 3 month period, 25.61% of total institutional ownership has changed in the company shares. On a different note, The Company has disclosed insider buying and selling activities to the Securities Exchange, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the CEO of Rockwell Medical, Inc., Chioini Robert L, had purchased 4,910 shares in a transaction dated on August 14, 2015. The transaction was executed at \$11.96 per share with total amount equaling \$58,724. Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patients bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol.

<u>----</u>